期刊文献+

白桦脂酸联合沙利度胺诱导U266细胞凋亡机制研究 被引量:1

Research on Betulinic Acid Combined with Thalidomide Induce Apoptosis of U266 Cells and Its Mechanism
下载PDF
导出
摘要 目的:探讨白桦脂酸联合沙利度胺诱导多发性骨髓瘤(MM)U266细胞凋亡的机制。方法:分别用白桦脂酸(20、40、60和80 mg/L,白桦脂酸组)、沙利度胺(10、50和100 mg/L,沙利度胺组)及白桦脂酸(40 mg/L)联合沙利度胺(联合组,白桦脂酸40 mg/L,沙利度胺10、50和100 mg/L)分别处理U266细胞,同期设对照组;MTT法和流式细胞术分别检测不同浓度白桦脂酸组、沙利度胺组及联合组U266细胞增殖抑制率和凋亡率;Real-time PCR检测4组U266细胞中Survivin、Cyto-C、Bcl-2、Bax mRNA的表达,蛋白免疫印迹法检测4组U266细胞中Survivin、Cyto-C、Bcl-2、Bax蛋白表达水平。结果:随着白桦脂酸浓度的增加,U266细胞增殖抑制率增加,差异有统计学意义(P<0.05),最适浓度为40 mg/L;与沙利度胺组相比,联合组U266细胞的增殖抑制率和凋亡率明显升高,差异具有统计学意义(P<0.05);与沙利度胺组或白桦脂酸组相比,联合组U266细胞中Survivin、Bcl-2 mRNA的表达明显降低,Cyto-C和Bax mRNA表达明显升高,差异具有统计学意义(P<0.05);与沙利度胺、白桦脂酸组相比,联合组U266细胞中Survivin、Bcl-2蛋白表达明显降低,Cyto-C和Bax蛋白表达明显升高,差异具有统计学意义(P<0.05)。结论:白桦脂酸联合沙利度胺可以促进多发性骨髓瘤U266细胞凋亡,其机制可能与凋亡分子Survivin、Bcl-2、Cyto-c和Bax相关。 Objective: To investigate the betulinic acid combined with Thalidomide induce apoptosis of U266 cells and its mechanism. Methods: U266 cells were treated with betulinic acid( 20,40,60 and 80 mg / L,betulinic acid group),Thalidomide( 10 mg / L,50 mg / L,100 mg / L,Thalidomide group) and betulinic acid( 40 mg / L) combined with Thalidomide( betulinic acid 40 mg / L,10,50 and 100 mg / L of Thalidomide,combined group) coupled with control group. Proliferation inhibition rate and apoptosis rate of U266 cells from different concentrations were detected with MTT and flow cytometry; Real-time PCR was used to detect the expression levels of Survivin,Cyto-C,Bcl-2,Bax gene. Western blotting was used to detect the expression of Survivin,Cyto-C,Bcl-2,Bax protein. Results: With the increase of betulinic acid concentration,inhibition rate of U266 cells was also increased,differences were statistically significant( P 0. 05),the most appropriate concentration was40 mg / L; comparing with Thalidomide,inhibition rate and apoptosis rate of U266 cells were obviously increased,differences were statistically significant( P 0. 05); comparing with Thalidomide group or betulinic acid group,Survivin and expression of Bcl-2 mRNA of U2666 cells obviously decreased,Cyto-C and expression of Bax mRNA obviously increased,differences were statistically significant( P 0.05). Conclusion: The betulinic acid combined with thalidomide induce apoptosis of multiple myeloma U266 cells and its mechanism may be correlated with the proapoptotic molecule of survivin,Bcl-2,Cyto-c and Bax.
出处 《贵阳医学院学报》 CAS 2015年第6期566-570,共5页 Journal of Guiyang Medical College
基金 国家自然科学基金(No.81360501)
关键词 白桦脂酸 沙利度胺 多发性骨髓瘤 U266细胞 增殖 凋亡 betulinic acid thalidomide multiple myeloma U266 cells proliferation apoptosis
  • 相关文献

参考文献17

  • 1Jasielec JK,Jakubowiak AJ.Current approaches to the initial treatment of symptomatic multiple myeloma[J].Int J Hematol Oncol,2013(1):133-139.
  • 2Durie BG.Role of new treatment approaches in defining treatment goals in multiple myeloma the ultimate goal is extended survival[J].Cancer Treat Rev,2010(36):18-23.
  • 3Berenson JR,Yellin O,Bessudo A,et al.Phase I/II trial assessing bendamustine bortezomib combination therapy for the treat.ment of patients with relapsed or refractory multiple myeloma[J].Br J Haematol,2013(3):321-330.
  • 4Mukherjee R,Kumar V,Srivastava SK,et al.Betulinic add derivatives as anticancer agents:structure activity relationship[J].Anticancer Agents Med Chem,2006(6):271-279.
  • 5Yogeeswari P,Sriram D.Betulinic acid and its derivatives:a review on their biological properties[J].Curr Med Chem,2005(6):657-666.
  • 6Kikuchi T,Akazawa H,Tabata K,et al.3-O-(E)-p-coumaroyl tormentic acid from eriobotrya japonica leaves induces caspase-dependent apoptotic cell death in human leukemia cell line[J].Chem Pharm Bull,2011(3):378-381.
  • 7Morgan GL,Davies FE,Gregory wM,et al.Firstline treatment with zoledronie acid as compared with clodronic acid in multiple myeloma(MRC Myeloma IX):a randomised controH ed trial[J].Lancet,2010(9757):744-751.
  • 8Durie BG,Harousseau JL,Miguel JS,et al.International uniform response criteria for multiple myeloma[J].Leukemia,2006(9):1467-1473.
  • 9Koren J,Spicka I,Straub J,et al.Retrospective analysis of there sults of high-dose chemotherapy with the support of autologous blood stem eeus in patients with multiple myeloma.The expe-Hence of a single centre[J].PragueM edRep,2010(3):207-218.
  • 10杨励,蔡真.多发性骨髓瘤的维持治疗[J].中华血液学杂志,2013,34(4):295-297. 被引量:6

二级参考文献67

  • 1Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma, 2007,48(2) :337-341.
  • 2Chanan-KhanAA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure:a multicenter retrospective study. Blood,2007, 109 (6):2604-2606.
  • 3Kastritis E, Anagnostopoulos A, Roussou M, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone- containing regimes and the impact of novel agents. Haematologica, 2007, 92(4):546-549.
  • 4Sengul S, Li M, Batuman V. Myeloma kidney: toward its prevention with new insights from in vitro and in vivo models of renal injury. Am J Nephrol,2009, 22(1) :17-28.
  • 5Morabito F, Gentile M, Ciolli S, et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol,2010, 84(3) :223-228.
  • 6Dimopoulos MA, Roussou M, Gavriatopoulou M, et aI. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive faetors. Clin Lymphoma Myeloma, 2009, 9 (4) : 302- 306.
  • 7Ludwig H, Adam Z, Hajek R, et al. Light chain-induced acute renal failure can he reversed by bortezomib-doxorubicin- dexamethasone in multiple myeloma:results of a phase Ⅱ study. J Clin Oncol,2010, 28(30) :4635-4641.
  • 8Roussou M, Kastritis E, Christoulas D, et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res, 2010, 34(10):1395- 1397.
  • 9Li J, Zhou DB, Jiao L, et al. Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment. Clin Lymphoma Myeloma, 2009,9 (5) : 394-398.
  • 10Qayum A, Aleem A, AI Diab AR, et al. Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib. Saudi J Kidney Dis Transpl, 2010, 21 (1) : 63-68.

共引文献10

同被引文献35

  • 1刘玉红,徐凌川,王建平,田景振.茶藨子叶孔菌化学成分的研究[J].中药材,2005,28(11):998-999. 被引量:22
  • 2郭华,侯冬岩,回瑞华,黄丹,李铁纯.环棱褐孔菌挥发性化学成分的分析[J].鞍山师范学院学报,2005,7(6):49-51. 被引量:4
  • 3刘玉红,徐凌川,王建平,田景振.茶藨子叶孔菌强酸性成分的研究[J].时珍国医国药,2006,17(9):1692-1693. 被引量:5
  • 4王筱菁,李万根,苏杭,苏涛.棕榈酸及亚油酸对人成骨肉瘤细胞MG63作用的研究[J].中国骨质疏松杂志,2007,13(8):542-546. 被引量:72
  • 5张小青,戴玉成.中国真菌志:第二十九卷[M].北京:科学出版社,2005:169.
  • 6Moon D,Hwang K,Choi K,et al.Some peroxysterols and ceramides from“Phellinus ribis”,a Korean wild mushroom[J].Anal Sci Tech,1995,8(4):901.
  • 7Liu YH,Wang FS.Structural characterization of an active polysaccharide from Phellinus ribis[J].Carbohydr Polym,2007,70(4):386.
  • 8Kubo M,Liu Y,lshida M,et al.A new spiroindene pigment from the medicinal fungus Phellinus ribis[J].Chem Pharm Bull:Tokyo,2014,62(1):122.
  • 9Zaidman BZ,Yassin M,Mahajna J,et al.Medicinal mushroom modulators of molecular targets as cancer therapeutics[J].Appl Microbiol Biotechnol,2005,67(4):453.
  • 10Takei T,Yoshida M,Ohnishi-Kameyama M,et al.Ergosterol peroxide,an apoptosis-inducing component isolated from Sarcodon aspratus(Berk.)S.Ito[J].Biosci Biotechnol Biochem,2005,69(1):212.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部